Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.

Calcifediol has been proposed as a potential treatment for COVID-19 patients. To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Retrospective, multicenter, open, non-randomized cohort study. Hospitalized care. Patients with labor...

Descripción completa

Detalles Bibliográficos
Autores: Alcala-Diaz, Juan F, Limia-Perez, Laura, Gomez-Huelgas, Ricardo, Martin-Escalante, Maria D, Cortes-Rodriguez, Begoña, Zambrana-Garcia, Jose L, Entrenas-Castillo, Marta, Perez-Caballero, Ana I, López-Carmona, Maria D, Garcia-Alegria, Javier, Lozano Rodríguez-Mancheño, Aquiles, Arenas-de Larriva, Maria Del Sol, Pérez-Belmonte, Luis M, Jungreis, Irwin, Bouillon, Roger, Quesada-Gomez, Jose Manual, Lopez-Miranda, Jose
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18353
Acceso en línea:http://hdl.handle.net/20.500.12105/18353
Access Level:acceso abierto
Palabra clave:COVID-19
COVID-19 drug treatment
SARS-CoV-2
calcifediol
vitamin D
Aged
Descripción
Sumario:Calcifediol has been proposed as a potential treatment for COVID-19 patients. To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Retrospective, multicenter, open, non-randomized cohort study. Hospitalized care. Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. In-hospital mortality during the first 30 days after admission. A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.

Similares en LA Referencia